Catalog No.:AA000O6P

1256580-46-7 | 9-Ethyl-6,6-dimethyl-8-[4-(morpholin-4-yl)piperidin-1-yl]-11-oxo-5H-benzo[b]carbazole-3-carbonitrile

Name: Name:9-Ethyl-6,6-dimethyl-8-[4-(morpholin-4-yl)piperidin-1-yl]-11-oxo-5H-benzo[b]carbazole-3-carbonitrile
Brand: AABLOCKS
SKU: AA000O6P
Availability: InStock
Rating: 90 (10 reviews)

Pack Size

Purity

Availability

Price(USD)

Quantity

250mg

98%

in stock

$70.00 $49.00

- +

98%

in stock

$140.00 $98.00

- +

98%

in stock

$610.00 $427.00

- +

10g

98%

in stock

$1,009.00 $706.00

- +

25g

98%

in stock

$2,007.00 $1,405.00

- +

Technical Information
Properties
Downstream Synthesis Route
Literature
Request for Quotation
Download SDS

Technical Information
Properties
Downstream Synthesis Route
Literature

Technical Information

Catalog Number:

AA000O6P

Chemical Name:

9-Ethyl-6,6-dimethyl-8-[4-(morpholin-4-yl)piperidin-1-yl]-11-oxo-5H-benzo[b]carbazole-3-carbonitrile

CAS Number:

1256580-46-7

Molecular Formula:

C30H34N4O2

Molecular Weight:

482.6166

MDL Number:

MFCD19440988

SMILES:

CCc1cc2C(=O)c3c4ccc(cc4[nH]c3C(c2cc1N1CCC(CC1)N1CCOCC1)(C)C)C#N

Properties

Computed Properties

Complexity:

867

Covalently-Bonded Unit Count:

Heavy Atom Count:

Hydrogen Bond Acceptor Count:

Hydrogen Bond Donor Count:

Rotatable Bond Count:

XLogP3:

5.2

Downstream Synthesis Route

1256580-24-1

1256580-46-7

[1]Patent:WO2019/8520,2019,A1.Locationinpatent:Page/Pagecolumn25

[2]BioorganicandMedicinalChemistry,2012,vol.20,p.1271-1280

6-cyano-2-{2-4-ethyl-3-(4-(morpholin-4-yl)piperidin-1-yl)phenylpropan-2-yl}-1H-indole-3-carboxylicacid

1256580-46-7

[1]Patent:CN107033124,2017,A.Locationinpatent:Paragraph0045-0046

[2]Patent:CN106928184,2017,A.Locationinpatent:Paragraph0023;0031;0036-0038;0043-0045;0050-0051

[3]Patent:CN110452215,2019,A.Locationinpatent:Paragraph0090-0096;0099;0100

[4]Patent:US2017/247352,2017,A1.Locationinpatent:Paragraph0028

[5]Patent:US2017/217927,2017,A1.Locationinpatent:Paragraph0171

[6]Patent:WO2019/38779,2019,A1.Locationinpatent:Page/Pagecolumn14

[7]Patent:CN108434136,2018,A.Locationinpatent:Paragraph0023;0024;0025

1256580-46-7

1256589-74-8

[1]Patent:US2013/143877,2013,A1.Locationinpatent:Paragraph0683;0684;0685

[2]Patent:US2017/217927,2017,A1.Locationinpatent:Paragraph0120;0121;0123;0124

[3]Patent:WO2019/8520,2019,A1.Locationinpatent:Page/Pagecolumn28;29

75-75-2

1256580-46-7

9-ethyl-6,6-dimethyl-8-(4-morpholin-4-yl-piperidin-1-yl)-11-oxo-6,11-dihydro-5H-benzobcarbazole-3-carbonitrilemonomesylatesalt

[1]Patent:US2013/143877,2013,A1.Locationinpatent:Paragraph0686

Literature

Title: Cytotoxicity of 34 FDA approved small-molecule kinase inhibitors in primary rat and human hepatocytes.

Journal: Toxicology letters 20180701

Title: 5-chloro-N4-(2-(isopropylsulfonyl)phenyl)-N2-(2-methoxy-4-(4-((4-methylpiperazin-1-yl)methyl)-1H-1,2,3-triazol-1-yl)phenyl)pyrimidine-2,4-diamine (WY-135), a novel ALK inhibitor, induces cell cycle arrest and apoptosis through inhibiting ALK and its downstream pathways in Karpas299 and H2228 cells.

Journal: Chemico-biological interactions 20180325

Title: ALK inhibitors in non-small cell lung cancer: the latest evidence and developments.

Journal: Therapeutic advances in medical oncology 20160101

Title: Alectinib: a review of its use in advanced ALK-rearranged non-small cell lung cancer.

Journal: Drugs 20150101

Title: Perfect ALKemy: optimizing the use of ALK-directed therapies in lung cancer.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20141115

Title: Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20141115

Title: Selective ALK inhibitor alectinib with potent antitumor activity in models of crizotinib resistance.

Journal: Cancer letters 20140901

Title: Design and synthesis of a highly selective, orally active and potent anaplastic lymphoma kinase inhibitor (CH5424802).

Journal: Bioorganic & medicinal chemistry 20120201

Title: CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant.

Journal: Cancer cell 20110517

Title: KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20090501

Title: Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.

Journal: Nature 20070802

Quotation Request

Company Name:

Contact Person:

Email:

Quantity Required:

Country:

Additional Info:

SDS